The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - Wikidata - awgldk - TriplyDB

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

http://www.wikidata.org/entity/Q28274089

about

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma Next-generation prognostic assessment for diffuse large B-cell lymphoma Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective Treatment of diffuse large B cell lymphoma Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma Next-generation surveillance strategies for patients with lymphoma Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research Diffuse large B-cell lymphoma: current strategies and future directions Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma.Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review.B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.

P2860

Q24599100-1BC49738-24CB-45D7-86A2-B0052AB967EF Q24646379-84289DF7-E6C8-47A3-BC30-607F385BCCEB Q26752284-C58447A2-D8B9-4A61-89A9-BC92BABB86D8 Q26771059-3BF57B25-566C-4108-A4BE-A682D6F56C42 Q26796428-69921D55-E482-4251-8E25-BCD035C6D8B5 Q26998446-7C32254B-8F79-4D67-AEDF-17A8384B29EC Q27006062-4A96641C-85C3-4C01-AACD-E6F9E54B5D7D Q27016561-0BC48FE5-D7E1-460D-9AEB-67C64F4D7FD8 Q27023579-86AED7D6-7F7A-4E78-B96D-B4B641C78513 Q27314782-EC9574E3-7B0A-4CA3-A5A4-5EED7B688658 Q27314809-91AF9C95-F990-4B28-9133-2445A7E0E607 Q28071905-91A80C91-55B2-4CAD-B9A4-66E0C6A3FCA8 Q28084956-D82FF702-C719-4AE5-8B4B-7D2BC7CB2EF8 Q28256567-CC51C5F8-FACC-4213-87C4-319B5FE9BD63 Q28266484-15D4FBB9-DA7F-4ABF-9647-B027367379A7 Q28269136-AFCBF7BB-8137-4D8E-BD69-A1F2DEE33FB5 Q28297940-58C34D84-42F7-4FDB-ACD6-364019273DAD Q30275206-CBC9C33E-17A0-4CCA-BDBF-97EE049AC2F4 Q30653421-5ACDEA00-9CDF-48F9-956F-A2A65F819A43 Q30967984-D48E7377-E441-4291-8960-08E95714C73E Q31116522-9E09DE63-3860-4A5F-B04D-A91913DC321E Q33396833-69F13FDE-648A-4072-995E-3E4ED9273970 Q33397845-91F56A44-40F3-41F1-B170-AD899B431DAF Q33406444-9BD920A5-9C9E-4588-9E95-622DE126A3DB Q33407197-B8319ED6-085B-4DBB-A14A-8FEC3E567213 Q33558130-7BDF4D21-1049-43D0-9C47-89A5EE1EFAF0 Q33587666-5BF96A22-B187-44ED-88CD-D97B28E50505 Q33608527-E9D6AA3A-E471-48E1-B20E-1771B0242F7A Q33622342-91A2D389-5F9A-4FF3-A067-E14D35FFC4B0 Q33625864-62992D86-34F1-41D6-BE71-3EFC2C95E90E Q33701858-272A807A-AFA6-4B5C-A5A1-FDCFE0AC2208 Q33701863-68BE7F87-E935-42C0-80DE-14745E43CBA6 Q33710715-875EB8E0-7449-451E-8F94-5F8D937162E3 Q33710720-475F6780-C339-40DE-86BF-4F48DD816D3A Q33718809-566B249E-8B07-41CC-A00F-A8773310F6E5 Q33739574-D4B711F3-CAC1-4486-9082-0F51DDD890E6 Q33809728-C65BDED4-1BBE-4CF4-B802-257307F9AC5B Q33846399-2B754425-66B7-42F8-AB6D-3D0166B11BD1 Q33846801-3D0985CE-D8FD-4DCA-A671-242E57A3808C Q33875883-0EF75A87-92A3-4E54-9C43-DCE97B1E807C

P2860

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

http://www.wikidata.org/entity/Q28274089

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

The revised International Prog ...... l lymphoma treated with R-CHOP

@ast

The revised International Prog ...... l lymphoma treated with R-CHOP

@en

The revised International Prog ...... l lymphoma treated with R-CHOP

@nl

type

label

The revised International Prog ...... l lymphoma treated with R-CHOP

@ast

The revised International Prog ...... l lymphoma treated with R-CHOP

@en

The revised International Prog ...... l lymphoma treated with R-CHOP

@nl

prefLabel

The revised International Prog ...... l lymphoma treated with R-CHOP

@ast

The revised International Prog ...... l lymphoma treated with R-CHOP

@en

The revised International Prog ...... l lymphoma treated with R-CHOP

@nl

P1433

Q28274089-694F68A5-2854-4EE8-8AF9-9BD53ECB01CA

P1476

Q28274089-8A9747BE-3D84-4063-91F9-07924E8A23CD

P2093

Q28274089-1DCD5F98-A652-4356-9309-237966C54FC3

Q28274089-1E003203-7005-459F-B65E-8A168F0EF90A

Q28274089-27147FCB-A7D6-4664-9E5B-6B9AC1587763

Q28274089-2B67296F-E3E2-402C-98D1-C27A451B1851

Q28274089-3A78571B-C79A-4827-953A-7611DF1D2F74

Q28274089-6FBF67D7-CCDD-4C40-AE9B-A32B89F36933

Q28274089-74D6F547-0F3D-499B-A93A-DE3E559F043A

Q28274089-923D0706-A740-4F36-A9E5-9BF6A853EA2A

Q28274089-A2623F80-662C-483B-99F9-F222A2267150

Q28274089-D572ECA6-CC53-42D4-A8D5-008F3D2E9D30

P304

Q28274089-009DD87E-E11D-4090-93CC-7C7156F13AEF

P31

Q28274089-003C100E-9BB1-4361-B196-CBEBA11694A4

P3181

Q28274089-7ACD3ADB-E754-455C-BC3B-57A60F1FD75F

P356

Q28274089-FC952124-A554-4D0E-9FAF-09BBC2CD9477

P407

Q28274089-3D3B5E99-1C89-4B7F-BC47-9E4BAA3C6F5C

P433

Q28274089-11ABB626-6A96-4119-9F8B-4DC53666CE3D

P478

Q28274089-02D4F629-2868-4B70-AEC0-B918F2D72795

P50

Q28274089-A08A598D-4241-4319-B971-3F705C9DC07A

Q28274089-B6BEAE7D-877A-4183-AF9D-2EEA27054AB1

P577

Q28274089-04763E97-6A53-4E87-8576-7742188E45E7

P5875

Q28274089-E8EC0E20-6FCB-4E90-9A91-CE350A61CA5F

P698

Q28274089-8FBD0CA1-9A51-4A8A-8FCD-6D0EB88C8672

P921

Q28274089-BC308AC9-D253-4AF2-9780-45CE387179BB

P3181

P356

BLOOD-2006-08-038257

P1433

P1476

The revised International Prog ...... l lymphoma treated with R-CHOP

@en

P2093

Brian Berry

http://www.w3.org/2001/XMLSchema#string

Catherine Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Judy Sutherland

http://www.w3.org/2001/XMLSchema#string

Karamjit Gill

http://www.w3.org/2001/XMLSchema#string

Kerry J Savage

http://www.w3.org/2001/XMLSchema#string

Laurie H Sehn

http://www.w3.org/2001/XMLSchema#string

Mukesh Chhanabhai

http://www.w3.org/2001/XMLSchema#string

Paul Hoskins

http://www.w3.org/2001/XMLSchema#string

Richard Klasa

http://www.w3.org/2001/XMLSchema#string

Tamara Shenkier

http://www.w3.org/2001/XMLSchema#string

P304

1857-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

289346

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2006-08-038257

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M Connors

Randy D Gascoyne

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6691558

http://www.w3.org/2001/XMLSchema#string

P698

17105812

http://www.w3.org/2001/XMLSchema#string

P921